^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD22-targeted CAR-T immunotherapy

    Related drugs:
    11d
    UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis (clinicaltrials.gov)
    P1, N=21, Recruiting, Nanjing IASO Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    18d
    A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Sheba Medical Center | Not yet recruiting --> Recruiting | Initiation date: Nov 2025 --> Feb 2026
    Enrollment open • Trial initiation date
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive
    25d
    CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial
    |
    CD22 (CD22 Molecule)
    |
    cyclophosphamide • fludarabine IV
    28d
    Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Tongji Hospital | Trial completion date: Oct 2027 --> Feb 2029 | Initiation date: Mar 2025 --> Feb 2026 | Trial primary completion date: Oct 2027 --> Feb 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    CD22 (CD22 Molecule)
    |
    cyclophosphamide • fludarabine IV
    1m
    Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients (clinicaltrials.gov)
    P1, N=68, Recruiting, University of Colorado, Denver | N=20 --> 68 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD19x22 CAR T
    2ms
    CD22 Redirected Autologous T Cells for ALL (clinicaltrials.gov)
    P1, N=41, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD22 (CD22 Molecule)
    2ms
    CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL (clinicaltrials.gov)
    P1, N=53, Recruiting, University of Colorado, Denver | N=26 --> 53
    Enrollment change
    |
    CD19x22 CAR T
    2ms
    Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Sana Biotechnology | Recruiting --> Active, not recruiting | N=35 --> 6 | Trial primary completion date: Mar 2028 --> Dec 2025
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    2ms
    Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=24, Recruiting, Ohio State University Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • TriCAR19.20.22 T cells
    3ms
    Sequential CD19/CD22 CAR-T Cell Therapy Following ASCT (clinicaltrials.gov)
    P2, N=23, Completed, The First Affiliated Hospital of Soochow University
    New P2 trial
    3ms
    A phase 2 trial of a "sandwich" strategy: Sequential CD22/CD19 chimeric antigen receptor T-cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. (PubMed, Cancer)
    The CD22/CD19 CAR T-cell and auto-HSCT sandwich strategy represents a promising approach for the treatment of Ph-negative B-ALL in AYA and adult patients, offering high efficacy and a favorable safety profile. The trial registration is ClinicalTrials.gov identifier NCT05470777.
    P2 data • Journal
    |
    CD22 (CD22 Molecule)
    |
    CD22/CD19 CAR T
    3ms
    Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies. (PubMed, Cytotherapy)
    CAR T-cell expansion was similar, except for patients who had extramedullary disease with low bone marrow disease burden (n = 6 from each group), for whom BC-manufactured cells had greater expansion. In summary, while efficacy across both platforms was comparable, lower inflammatory markers in those who received Prodigy manufactured CAR T-cells suggest changes in the infusion product.
    Journal
    |
    CD22 (CD22 Molecule) • CRP (C-reactive protein)
    |
    firicabtagene autoleucel (CRG-022)